Clinical trials
Mutation clinical trials
Below are recruiting mutation clinical trials, each written for real people, not researchers. We’re tracking 742 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Anchorage, AlaskaAges 18 years+ - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Birmingham, AlabamaAges 18 years+ - NCT07659795RecruitingPhase 2
Study of VS-7375 for KRAS G12D colorectal cancer
This trial tests a new targeted pill, VS-7375, for people with a specific type of advanced colorectal cancer called KRAS G12D. It's for those who either haven't had treatment yet or whose cancer has worsened after prior therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT06791161Enrolling by invitation
Adjuvant therapy study for BRCA1/2 positive breast cancer
This study tests if additional treatment after surgery helps prevent breast cancer from returning. It is for people with hormone receptor-positive, HER2-negative breast cancer who have a BRCA1 or BRCA2 gene mutation and a high risk of recurrence.
Beijing, Beijing MunicipalityAges 18–75 - NCT06362980RecruitingPhase 1
BPI-1178 plus osimertinib for EGFR-mutated lung cancer
This trial tests a new drug (BPI-1178) combined with osimertinib for advanced lung cancer with EGFR mutations. It’s for people whose cancer has progressed after prior treatment with a third-generation EGFR targeted therapy.
BeijingAges 18 years+ - NCT06069505Recruiting
Testing for drug-resistant fungus in blood or fluid
This study is testing a new blood or fluid test that may find drug-resistant fungus in people with a weakened immune system who have a serious lung infection. The results could help doctors choose the right medicine faster.
Rotterdam, South HollandAges 18 years+ - NCT06020625Recruiting
Genetic testing for advanced cancers
This trial investigates genetic testing (mutational profiling) in people with various advanced cancers. It aims to understand how these tests can guide more personalized treatment decisions.
RomeAges 18 years+ - NCT05929365Recruiting
Test genetic marker tracking to find returning colon polyps
This study looks at stool or tissue DNA changes (called mutation analysis) plus colonoscopy findings to detect whether colon polyps come back. It may help catch recurrent colorectal lesions earlier during surveillance after a large polyp was removed.
PragueAges 18–75 - NCT04712877Recruiting
Blood and tumor testing to choose the right lung cancer treatment
This trial tests tumor tissue and a blood sample to help doctors pick the most personalized treatment for people with suspected lung cancer. It may help ensure you get therapy matched to your specific tumor characteristics, especially when the cancer might be surgically removed.
Davis, CaliforniaAges Any age - NCT05420779RecruitingPhase 2
TSL-1502 for breast cancer with BRCA gene mutations
This Phase 2 trial tests TSL-1502 capsules, a targeted medicine for breast cancer, in people whose blood test shows a harmful BRCA gene mutation. It aims to see whether it can control the cancer and how safe it is after prior treatment.
BeijingAges 18–75 - NCT05247112Recruiting
Tracking antibiotic resistance in H. pylori infections in Korea
This study looks at how resistant H. pylori (a stomach germ) is to different antibiotics in Korea. It uses stomach endoscopy samples to test which antibiotics may or may not work, helping guide future treatment choices.
Seongnam-si, Gyeonggi-doAges Any age - NCT05382728RecruitingPhase 3
Test drug for EGFR-mutant lung cancer without prior treatment
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
Changsha, HunanAges 18–80 - NCT05600764Recruiting
Study of how TRPV4 nerve disease develops over time
This study looks at the natural history of TRPV4-related neuropathy—how it starts and changes over time. It may help doctors better understand the condition, especially for people with TRPV4 gene changes.
Baltimore, MarylandAges 3–80 - NCT04216121Recruiting
Testing a focused radiation approach for limited cancer spread
This trial looks at using a targeted form of radiation (LAT, often like SBRT) for people whose lung cancer has spread in only a few places while on osimertinib. It aims to control those “limited progression” spots and help you stay on the same medicine longer.
LeuvenAges 18 years+ - NCT05504278RecruitingPhase 1
Testing IBI351 with chemotherapy for KRAS G12C lung cancer
This Phase 1 study tests whether IBI351, a targeted medicine, can be safely given with standard chemotherapy to treat advanced lung cancer that has a KRAS G12C mutation. It’s mainly looking at safety and early signs of effectiveness, and may offer a new option if your cancer matches these features.
Jilin City, ChangchunAges 18–75 - NCT03810339RecruitingPhase 2
Check a POLE/POLD cancer drug for non–MSI-high tumors
This Phase 2 trial studies toripalimab (JS001), given alone, in people whose tumors have specific POLE or POLD gene mutations but do not have MSI-H/dMMR. If it works, it may help shrink or control advanced solid tumors that have not responded to standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT04678583Recruiting
Surgery plan for RAS-mutant colon cancer liver metastases
This trial studies an approach to surgically removing liver metastases from colon (or rectal) cancer that has an RAS gene mutation (KRAS or NRAS). If you qualify, you would be evaluated for whether a “complete” (R0) liver operation is planned and technically possible, aiming to improve cancer control by how the liver is cut.
Mannheim, Baden-WurttembergAges 18 years+ - NCT04286360Recruiting
Study blood findings in children with genetic rasopathies
This study looks at blood and other hematologic (blood-related) findings in children who are newly diagnosed with certain genetic conditions called rasopathies. It may help doctors understand what blood changes are common early on and how to monitor them.
AngersAges Up to 15 years - NCT06962254RecruitingPhase 1
Imatinib and Trametinib for KRAS-mutated solid tumors
This trial tests a combination of two targeted drugs, imatinib and trametinib, for people with advanced solid tumors that have a specific KRAS mutation (G12X). It may be an option if standard treatments have stopped working or are not available.
Taichung, TaichungAges 20 years+ - NCT03478761Recruiting
Registry for people with CYP24A1 vitamin D–related kidney stone risk
This is a research registry for people who have a confirmed CYP24A1 genetic change tied to high calcium and kidney stone problems. It helps researchers better understand who is affected and may guide future studies or care approaches.
Rochester, MinnesotaAges Any age - NCT03538639Recruiting
Study blood and tissue samples for vascular disease discovery
This study collects blood (and sometimes tissue samples) from people who may have vascular (blood vessel) problems and from certain pregnant participants. Researchers use the samples to better understand vascular disease and to help guide future research.
Bethesda, MarylandAges 2–100 - NCT02215928Recruiting
Using tumor genetic tests to guide treatment choices
This study looks at your tumor’s genetic information to help doctors recommend treatment for cancers that have spread. It may help you get the most suitable therapy based on what’s found in your tumor.
Palo Alto, CaliforniaAges 18 years+ - NCT06262919Recruiting
Monitoring safety of Tafinlar/Mekinist for BRAF-positive tumors
This study tracks the safety of the combination therapy Tafinlar and Mekinist in people with advanced or returning solid tumors that have a BRAF mutation, except for colorectal cancer. It aims to make sure the treatment is safe in the real world.
Nagakute, Aichi-kenAges 6–99
Hear when a new Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mutation?
- Yes. Clin2 currently lists 742 recruiting mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.